abbott semaglutide × Novo Nordisk 🤝 just entered its next growth phase in India. This isn't just a product launch. It's a distribution-led expansion strategy in one of the fastest-growing cardiometabolic markets Novo Nordisk and Abbott Launch

This compounded preparation: Has not been approved by the FDA Has not undergone FDA review for safety, effectiveness, or quality Is prepared specifically for you based on your prescriber's order Individual outcomes may vary Dosing is determined by the prescribing provider based on patient-specific factors

The FDA has reported a significant increase in semaglutide-related dosing errors , with some individuals injecting five to twenty times their prescribed dose

Avoid pharmacies that cant provide verifiable license numbers

GLP-1 receptors are abundant in the gastrointestinal tract, and semaglutide's activation of these receptors alters gut motility and the overall digestive process

Followup & labs A1C, weight, and tolerability are reviewed periodically to tailor therapy

Avoid injecting while standing, as this tenses the thigh muscles and thins the fat layer